

## **Bulletin from the Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ)**

**12 January 2021 – The Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ) was held on 12 January 2021 at the offices of Setterwalls Advokatbyrå at Sturegatan 10, Stockholm. Attendance at the meeting was solely possible via postal voting. The following resolutions were passed at the general meeting.**

### **Resolution to amend the articles of association**

The general meeting resolved, in accordance with the board of director's proposal, to amend the Company's articles of association with respect to, *inter alia*, prerequisites for participation at general meetings, the limits for the share capital and number of shares.

The general meeting resolved on a total of two separate amendments of the articles of association, of which one of the amendments is conditional upon the board of directors, by utilizing the authorisation from the general meeting, resolving on an issue of shares resulting in that the number of shares and share capital exceeds the boundaries stipulated in the articles of association (the version which was adopted at the general meeting held on 12 January 2021 and which is not conditional upon the board resolving on a new issue of shares).

### **Resolution to authorize the board of directors to issue shares with preferential rights for the shareholders**

The general meeting resolved, in accordance with the board of director's proposal, to authorise the board of directors, for the period up to the next annual general meeting, to increase the Company's share capital through issuing new shares with preferential rights for the Company's shareholders. Payment shall be made by cash or through payment in kind, by set-off or subject to other conditions.

Issuance by virtue of the authorization can include no more than as many shares that can be issued without changing the, at the time of the issue, adopted articles of association. The purpose of the authorization is to enable a capital raise in the Company as efficiently as possible to enable further development of the Company's business.

### **For more information:**

Peter Zerhouni, CEO

E-mail: [peter.zerhouni@indexpharma.com](mailto:peter.zerhouni@indexpharma.com)

Phone: +46 (0) 8 122 038 50

*The information was submitted for publication, through the agency of the contact person above, on 12 January 2021 at 12:30 (CET).*

### **InDex Pharmaceuticals Holding AB (publ) in brief**

InDex is a pharmaceutical development Company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The Company's lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The Company's shares (ticker INDEX) are traded on Nasdaq First North Growth Market. Redeye AB with email address [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se) and phone number +46 8 121 576 90 is the Company's Certified Adviser. For more information, please visit <http://www.indexpharma.com>.